JP6542827B2 - 可逆的に架橋されたミセル系 - Google Patents

可逆的に架橋されたミセル系 Download PDF

Info

Publication number
JP6542827B2
JP6542827B2 JP2017058554A JP2017058554A JP6542827B2 JP 6542827 B2 JP6542827 B2 JP 6542827B2 JP 2017058554 A JP2017058554 A JP 2017058554A JP 2017058554 A JP2017058554 A JP 2017058554A JP 6542827 B2 JP6542827 B2 JP 6542827B2
Authority
JP
Japan
Prior art keywords
peg
acid
ptx
nanocarrier
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017058554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017149960A (ja
JP2017149960A5 (enExample
Inventor
エス.ラム キット
エス.ラム キット
ユアンペイ リ
ユアンペイ リ
チュンタオ ルオ
チュンタオ ルオ
カイ シャオ
カイ シャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017149960A publication Critical patent/JP2017149960A/ja
Publication of JP2017149960A5 publication Critical patent/JP2017149960A5/ja
Application granted granted Critical
Publication of JP6542827B2 publication Critical patent/JP6542827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers
    • C08G83/004After treatment of dendrimers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
JP2017058554A 2011-05-13 2017-03-24 可逆的に架橋されたミセル系 Active JP6542827B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161485774P 2011-05-13 2011-05-13
US61/485,774 2011-05-13
US201161487953P 2011-05-19 2011-05-19
US61/487,953 2011-05-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014510540A Division JP6235460B6 (ja) 2011-05-13 2012-05-14 可逆的に架橋されたミセルsystems

Publications (3)

Publication Number Publication Date
JP2017149960A JP2017149960A (ja) 2017-08-31
JP2017149960A5 JP2017149960A5 (enExample) 2018-01-11
JP6542827B2 true JP6542827B2 (ja) 2019-07-10

Family

ID=47177586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017058554A Active JP6542827B2 (ja) 2011-05-13 2017-03-24 可逆的に架橋されたミセル系

Country Status (5)

Country Link
US (2) US10106650B2 (enExample)
EP (1) EP2707419B1 (enExample)
JP (1) JP6542827B2 (enExample)
CN (1) CN103748142B (enExample)
WO (1) WO2012158622A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557292B2 (en) 2008-08-13 2013-10-15 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
CN103748142B (zh) 2011-05-13 2016-04-27 加利福尼亚大学董事会 可逆交联的胶束系统
CA2843503C (en) * 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
CN104105508B (zh) 2011-12-21 2017-10-24 加利福尼亚大学董事会 药物递送增强的末端树枝状聚合物
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
JP6251295B2 (ja) * 2013-03-01 2017-12-20 カリフォルニア インスティテュート オブ テクノロジー ニトロフェニルボロン酸組成物によって安定化したナノ粒子
EP2961395B1 (en) * 2013-03-01 2024-06-19 California Institute Of Technology Targeted nanoparticles
WO2014185964A1 (en) * 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
CN104414973A (zh) * 2013-08-21 2015-03-18 复旦大学 一种视黄酸和紫杉醇共递药的胶束给药系统及其制备方法
US11406714B2 (en) 2013-08-21 2022-08-09 The Research Foundation For The State University Of New York Telodendrimers and nanocarriers and methods of using same
CN105193732A (zh) * 2014-06-05 2015-12-30 华东理工大学 雷帕霉素纳米缓释微球及其制备方法
WO2016050210A1 (zh) * 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
CN104530413B (zh) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN104530417B (zh) * 2014-10-01 2017-09-08 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物及其制备方法
WO2016050208A1 (zh) * 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物修饰的生物相关物质
WO2016057657A1 (en) 2014-10-07 2016-04-14 The Research Foundation For The State University Of New York Functional segregated telodendrimers and nanocarriers and methods of making and using same
ES2980216T3 (es) 2015-07-01 2024-09-30 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
ES2625024B1 (es) * 2015-12-18 2018-05-10 Consejo Superior De Investigaciones Cientificas Material que comprende tectómeros de oligoglicina y nanohilos
WO2017149546A1 (en) * 2016-03-03 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Multi drug composite, preparation methods and uses thereof
US10583083B1 (en) * 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US10517823B1 (en) 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US11369688B2 (en) * 2016-09-15 2022-06-28 The Regents Of The University Of California Hybrid telodendrimers
US11369614B2 (en) 2017-01-19 2022-06-28 The Research Foundation For The State University Of New York Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same
JP2018070626A (ja) * 2017-11-24 2018-05-10 カリフォルニア インスティテュート オブ テクノロジー 標的化ナノ粒子
JP7525981B2 (ja) * 2017-11-24 2024-07-31 カリフォルニア インスティテュート オブ テクノロジー ニトロフェニルボロン酸組成物によって安定化したナノ粒子
JP2018058868A (ja) * 2017-11-24 2018-04-12 カリフォルニア インスティテュート オブ テクノロジー ニトロフェニルボロン酸組成物によって安定化したナノ粒子
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
US12023411B2 (en) 2018-08-13 2024-07-02 Polymer Factory Sweden Ab Dendritic nanogel carriers and method of production
CN111184874B (zh) * 2018-11-14 2022-02-22 南京大学 疏水性纳米生物探针
US11179475B2 (en) 2018-11-28 2021-11-23 International Business Machines Corporation Biodegradable functional polycarbonate nanoparticle carries for delivering molecular cargo
JP2019108371A (ja) * 2019-03-04 2019-07-04 カリフォルニア インスティテュート オブ テクノロジー 標的化ナノ粒子
CN111904932B (zh) * 2019-05-08 2023-06-20 北京德立福瑞医药科技有限公司 一种含有糖皮质激素的胶束制剂及其制备方法
EP4069707A4 (en) 2019-12-04 2023-12-06 Dantari, Inc. METHOD AND COMPOSITIONS FOR SYNTHESIS OF THERAPEUTIC NANOPARTICLES
EP4077477A4 (en) * 2019-12-17 2024-05-08 The Regents Of The University Of California Sequential targeting in crosslinking nano-theranostics for treating brain tumors
EP4429798A1 (en) * 2021-11-09 2024-09-18 Massachusetts Institute of Technology Particles containing pollutant-capturing micelles and related methods
WO2023133096A1 (en) * 2022-01-04 2023-07-13 The Research Foundation For The State University Of New York Cmt-3 formulations and methods of using the same
CN115531291B (zh) * 2022-09-02 2025-02-14 南京医科大学 一种可载药的赖氨大黄酸自组装水凝胶及其制备方法与应用
WO2024254448A2 (en) * 2023-06-07 2024-12-12 The Research Foundation For The State University Of New York Boronate prodrug nanoformulations in disease treatments
CN121064464A (zh) * 2025-11-06 2025-12-05 北京师范大学珠海校区 一种基于天然分子胆酸的抗菌牙科树脂材料

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100396171B1 (ko) 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
JP4659937B2 (ja) 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US7846893B2 (en) * 2005-02-16 2010-12-07 Rutgers, The State University Of New Jersey Drug-polymer conjugates coupled to a peptidic carrier
US8153110B2 (en) 2006-11-22 2012-04-10 The University Of Tokyo Environment-responding siRNA carrier using disulfide-cross-linked polymeric micelle
US9579400B2 (en) * 2008-09-23 2017-02-28 The Regents Of The University Of California Nanocarriers for drug delivery
US9296988B2 (en) 2009-06-19 2016-03-29 The Regents Of The University Of California Three-dimensional cell adhesion matrix
CN103748142B (zh) 2011-05-13 2016-04-27 加利福尼亚大学董事会 可逆交联的胶束系统

Also Published As

Publication number Publication date
EP2707419A4 (en) 2014-11-26
EP2707419A2 (en) 2014-03-19
EP2707419B1 (en) 2019-08-14
JP2014514431A (ja) 2014-06-19
CN103748142B (zh) 2016-04-27
US10106650B2 (en) 2018-10-23
JP6235460B2 (ja) 2017-11-22
WO2012158622A2 (en) 2012-11-22
JP2017149960A (ja) 2017-08-31
CN103748142A (zh) 2014-04-23
US20150045419A1 (en) 2015-02-12
US20190112423A1 (en) 2019-04-18
WO2012158622A3 (en) 2013-03-28
US11192978B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
JP6542827B2 (ja) 可逆的に架橋されたミセル系
US11219692B2 (en) Porphyrin modified telodendrimers
JP5539993B2 (ja) 薬物送達のためのナノ担体
EP2793953B1 (en) Telodendrimers with enhanced drug delivery
US11369688B2 (en) Hybrid telodendrimers
JP6235460B6 (ja) 可逆的に架橋されたミセルsystems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190613

R150 Certificate of patent or registration of utility model

Ref document number: 6542827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250